Fluorine Reagents for Cesium Isotope Separation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for separating cesium from aqueous fluids, particularly radioactive isotopes like Cs-134, Cs-135, and Cs-137, are inefficient and pose environmental and health risks due to slow excretion and high mobility of cesium ions in the body.
Innovation Solution
The use of perfluorinated phenyl rings in large anionic ligands to form water-insoluble cesium salts through chelating interactions, specifically with fluoroarylboronate anions, which selectively bind to cesium ions, allowing for their quantitative separation from other alkali metals and radioactive waste.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional separation methods are used for cesium from aqueous fluids, then the separation process is simple, but the separation efficiency is low and radioactive isotopes remain in the fluid
Solution Approach 1:
The patent changes the chemical parameters by introducing fluorine-containing reagents that form water-insoluble salts with cesium ions. This parameter change transforms the solubility characteristics of cesium compounds, enabling efficient separation from aqueous fluids through precipitation rather than complex multi-step processes
Solution Approach 2:
The patent uses fluorine-containing reagents that selectively bind to cesium ions to form insoluble salt compounds. This creates a copy of the cesium in an insoluble form that can be easily separated from the aqueous phase, achieving high separation efficiency without complex equipment
2Reliability
If cesium ions are administered for therapeutic use, then the therapeutic effect is achieved, but the retention time in the body is long causing radiation damage
Solution Approach 1:
The patent introduces fluorine-containing compounds as intermediary substances that bind to cesium ions in the body. These compounds act as mediators to accelerate the excretion of radioactive cesium by forming compounds that are rapidly eliminated through urine, thereby reducing radiation exposure time
Solution Approach 2:
The patent accelerates the excretion process of cesium ions by using fluorine-containing reagents that create water-insoluble salts. This rushing through the retention period quickly eliminates radioactive isotopes from the body, minimizing the time for radiation damage to occur
3Productivity
If Prussian blue is used to remove cesium ions, then excretion is accelerated, but the mobility of cesium ions in the body causes re-absorption
Solution Approach 1:
The patent changes the chemical form of cesium by forming water-insoluble fluorine-containing salts. This parameter change reduces the mobility and re-absorption tendency of cesium ions while maintaining rapid excretion, as the insoluble compounds are quickly eliminated through urine without being re-absorbed
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method significantly reduces the retention time of cesium ions in the body, enhancing excretion and providing a safer, more efficient means of removing cesium from both biological and nuclear waste systems, with applications in decontamination and radiopharmaceuticals.
Implementation Method 1
The use of perfluorinated phenyl rings in large anionic ligands to form water-insoluble cesium salts through chelating interactions
Implementation Method 2
forming water-insoluble cesium salts... allowing for their quantitative separation from other alkali metals and radioactive waste
Implementation Method 3
This method significantly reduces the retention time of cesium ions in the body, enhancing excretion
Data Source
AI summary
The present invention refers to a process for removing Cs, and optionally Rb, from aqueous fluids including body fluids by fluorine containing reagents, the synthesis of fluorine containing, water-insoluble salts of said Cs isotopes and their use as therapeutic agents.